Routine

Solitary pulmonary nodule / incidental lung nodule — assessment

pulmonary-nodule · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Approach to a discrete rounded opacity <=3 cm surrounded by aerated lung (nodule; >3 cm = mass, treat as malignant until proven otherwise). The task is to estimate malignancy risk from nodule features and patient risk factors, then follow a structured surveillance/biopsy pathway. Most small nodules are benign, but incidental detection is common and anxiety-provoking.

Red flags

  • Spiculated margins, rapid growth, or size >8 mm in a smoker/ex-smoker
  • Associated lymphadenopathy, effusion, or weight loss/haemoptysis
  • Prior malignancy (consider metastasis)
  • Nodule enlarging on surveillance
  • Patient lost to follow-up (system risk)

Assessment

Differential diagnosis

  • Benign: granuloma (old TB/fungal), hamartoma, intrapulmonary lymph node, infection/inflammation, rounded atelectasis, AVM
  • Malignant: primary lung cancer, solitary metastasis, carcinoid
  • Active infection/TB (esp. India) - consider in endemic settings
  • Vasculitis/rheumatoid nodule

Investigations

  • Characterise on CT: size, growth (vs any prior imaging - ESSENTIAL), solid vs sub-solid/ground-glass, margins (spiculated = higher risk), calcification pattern (benign if central/laminated/popcorn), location (upper lobe higher risk)
  • Compare with ALL available old imaging - stability over 2 years (solid) strongly suggests benign
  • Risk stratify with patient factors: age, smoking, prior malignancy, family history, asbestos exposure (use a validated model e.g. Brock)
  • PET-CT for solid nodules >8 mm of intermediate risk (metabolic activity; also stages if malignant)
  • Consider CT-guided or bronchoscopic biopsy for accessible higher-risk nodules
  • Sputum/tests for TB and fungal disease where endemic/suggested
  • Baseline bloods; MDT discussion

Management

  • Confirm it is a true nodule and seek prior imaging to assess growth and stability
  • Estimate malignancy probability from nodule characteristics + patient risk factors (validated model)
  • Very small / low-risk solid nodules (<6 mm): no or interval CT follow-up depending on risk (per Fleischner Society guidance)
  • Intermediate solid nodules (6-8 mm): CT surveillance at defined intervals
  • Solid nodules >8 mm, intermediate/high risk: PET-CT and/or biopsy/MDT; resect if high probability
  • Sub-solid/ground-glass nodules: longer surveillance intervals (indolent adenocarcinoma spectrum)
  • In TB/fungal-endemic areas keep infection in the differential and investigate accordingly before labelling malignant
  • Refer suspicious nodules to a lung-cancer MDT / respiratory clinic; definitive management (resection, SABR, systemic therapy) per staging
  • Document a clear surveillance plan and ensure follow-up is not lost

Drugs & doses

No drug treatment for the nodule itself - this is a diagnostic/surveillance pathway
Empirical anti-tuberculous or antifungal therapy only if an infective cause is diagnosed (-> relevant pathway)
Analgesia/periprocedural cover for biopsy as per local protocol

Disposition

Outpatient. Communicate a clear surveillance plan or refer to lung-cancer MDT/respiratory clinic for intermediate/high-risk nodules. Ensure robust follow-up tracking.

Complications & pitfalls

  • Delayed diagnosis of early, curable lung cancer
  • Over-investigation of benign nodules (biopsy complications: pneumothorax, bleeding; radiation; anxiety)
  • Loss to follow-up of a surveillance nodule

Exam pearls

  • Finding and comparing PRIOR imaging is the single most useful step - a solid nodule stable for >=2 years is almost always benign (Fleischner Society 2017 guidance).
  • Benign calcification patterns (central, laminated, popcorn) and fat (hamartoma) are reassuring; spiculation and upper-lobe location raise risk.
  • Use a validated risk model (e.g. Brock) plus PET-CT for solid nodules >8 mm to guide biopsy vs surveillance.
  • Sub-solid/ground-glass nodules behave indolently and need longer surveillance, not immediate biopsy.
  • In TB-endemic regions, a granuloma is a common benign cause - but never assume; exclude malignancy if features are atypical.
  • A mass (>3 cm) is managed as cancer until proven otherwise - not as a 'nodule'.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.